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Abstract
Background: Informed consent (IC) has been an international standard for decades for the ethical conduct of clinical trials.
Yet frequently study participants have incomplete understanding of key issues, a problem exacerbated by language barriers
or lack of familiarity with research concepts. Few investigators measure participant comprehension of IC, while even fewer
conduct interim assessments once a trial is underway.
Methods and Findings: We assessed comprehension of IC using a 20-question true/false quiz administered in 6-month
intervals in the context of a placebo-controlled, randomized trial for the prevention of tuberculosis among HIV-infected
adults in Botswana (2004–2009). Quizzes were offered in both Setswana and English. To enroll in the TB trial, participants
were required to have $16/20 correct responses. We examined concepts understood and the degree to which
understanding changed over three-years. We analyzed 5,555 quizzes from 1,835 participants. The participants’ highest
education levels were: 28% primary, 59% secondary, 9% tertiary and 7% no formal education. Eighty percent of participants
passed the enrollment quiz (Quiz1) on their first attempt and the remainder passed on their second attempt. Those having
higher than primary education and those who took the quiz in English were more likely to receive a passing score on their
first attempt (adjusted odds ratios and 95% confidence intervals, 3.1 (2.4–4.0) and 1.5 (1.2, 1.9), respectively). The trial’s
purpose or procedures were understood by 90–100% of participants, while 44–77% understood randomization, placebos, or
risks. Participants who failed Quiz1 on their initial attempt were more likely to fail quizzes later in the trial. Pass rates
improved with quiz re-administration in subsequent years.
Conclusions: Administration of a comprehension quiz at enrollment and during follow-up was feasible in a large,
international collaboration and efficiently determined IC comprehension by trial participants. Strategies to improve
understanding of concepts like placebos and randomization are needed. Comprehension assessments throughout a study
may reinforce key concepts.
Citation: Chaisson LH, Kass NE, Chengeta B, Mathebula U, Samandari T (2011) Repeated Assessments of Informed Consent Comprehension among HIV-Infected
Participants of a Three-Year Clinical Trial in Botswana. PLoS ONE 6(10): e22696. doi:10.1371/journal.pone.0022696
Editor: Landon Myer, University of Cape Town, South Africa
Received January 20, 2011; Accepted July 5, 2011; Published October 27, 2011
This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for
any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.
Funding: This analysis of comprehension quizzes was funded by the Centers for Disease Control and Prevention (CDC) Division of TB Elimination as well as by a
student grant from the Merck Summer Scholars program at Johns Hopkins University. The funders had no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: nkass@jhu.edu
Introduction
Background
The protection of human subjects in medical research is a
fundamental concern of bioethics. Informed consent is one means
of providing such protection. Through the delivery of key study
information, informed consent allows potential participants, based
on their own values, to decide which risks, benefits, and
procedures are acceptable to them. While informed consent is
expected to be a dialogue between researcher and potential
participant, consent information is typically provided through a
written consent form as well, which is also used to document the
participant’s agreement to enroll in the study.
While informed consent documents are useful as a means of
standardizing information, research participants in multiple
settings and in multiple studies have been shown to have
incomplete or inaccurate understanding of many facets of
information provided through the informed consent process [1–
5]. Unfamiliar terms such as randomization and placebo are
particularly hard to understand [6–9], as are concepts related to
risks [10,11], benefits [12–14], and the freedom to withdraw from
the study [15–18]. Additionally it has been shown that many trial
participants are unaware that they are enrolled in research [18–
20]. Incomplete and/or inaccurate understanding has been
attributed to several factors, including unfamiliarity with research,
low levels of education, hopes for clinical benefit, and problems
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such problems exist in both developed and developing country
contexts, they may be amplified in international settings where
language barriers or lack of familiarity with research itself may
make understanding of research concepts harder to achieve
[3,25–27].
Further hampering research understanding is the decrease in
the ability to remember study information over time [28–31]. As
such, the Council for International Organizations of Medical
Sciences (CIOMS) international ethical guidelines for research
emphasizes the continuous nature of informed consent [32]. It is
unclear whether the investigators of longitudinal studies review
important information with trial participants after studies have
begun [29], and we are not aware of any regulations or guidelines
that formally require this in longitudinal projects [29,33]. The
difficulty of ensuring adequate comprehension of study informa-
tion has led some investigators to recommend that participants’
understanding be assessed after consent discussions have occurred,
but prior to enrollment [11,34–36]. While researchers report
believing that testing understanding is important, limited evidence
suggests that only a minority of researchers actually engage
formally in an assessment process [37–40]. A small number of
investigators have published findings from attempts to measure
participants’ understanding prior to enrollment, with an even
smaller number having conducted interim assessments once
research is underway [36,41,42].
A clinical trial conducted in Botswana from 2004–2009
provided an opportunity to examine how well participants
understood study information when first told about the study,
and to measure their understanding over time. The Isoniazid
Prevention Therapy (IPT) trial, part of an ongoing collaboration
between the U.S. Centers for Disease Control and Prevention
(CDC) and the Botswana Ministry of Health, was a randomized,
double-blind, placebo-controlled study of limited (6 months) vs.
continuous (36 months) IPT among HIV-infected persons $18
years of age. This three-year study allowed investigators to detect
any differences in rates of active TB incidence between the two
study arms. Participation involved monthly clinic visits over the 36
months. The informed consent form for the trial was first
developed in English by study investigators, translated into
Setswana, and back-translated into English to ensure consistency
of meaning.
In an effort to ensure that participants adequately understood
study information, investigators developed a 20 item true/false
comprehension quiz to administer following the informed consent
discussion, but prior to enrollment. To be able to join the study,
participants had to be able to answer at least 16 of the 20 items
correctly on the quiz. Potential participants who failed further
discussed the protocol with study nurses, and were then allowed to
repeat the quiz. Those who failed the quiz twice were not allowed
to enroll in the clinical trial.
This manuscript reports on the analysis of the comprehension
quiz data. Specifically, we examined the extent to which
participants obtained a passing quiz score at enrollment, factors
associated with passing or failing scores, likelihood of retaining
study information over time, and which questions were most likely
to be answered correctly and incorrectly.
Methods
IPT Trial
Recruitment for the IPT trial took place from 2004 through
2006. In December 2006, the investigators amended the study
protocol such that the comprehension test was re-administered to
study subjects every 6 months throughout the remainder of their
time in the trial, allowing investigators to measure participants’
understanding of the study over time. Participants were not
removed from the study at this stage if a passing score ($16/20
correct responses) was not obtained, but nurses reviewed relevant
information with participants, allowing reinforcement of informa-
tion that had been either forgotten or misunderstood. As the
decision to re-administer the quiz every 6 months was made 2
years after enrollment began, participants who enrolled in 2004
received their first follow-up quiz about 2 years into the study (and
subsequently at months 30 and 36). Subjects who first enrolled in
2006 were re-quizzed every 6 months after enrollment, for a total
of up to 6 quizzes.
Data collection
Data for this study consisted of all available enrollment and
follow-up quizzes from participants in the IPT trial. Data were
abstracted from the hard copy paper quizzes in July 2008 from the
2 study sites in Gaborone and Francistown, Botswana, and were
entered into a Microsoft Access database. Original paper quizzes
had no participant-identifying information and had been labeled
with a participant identification number (ID) and housed in locked
warehouses. Data abstracted included variables present on the
comprehension quiz: participant ID; day, month, and year that
the quiz was administered; answers the participant gave for each of
the 20 true/false quiz items; and language of administration
(English or Setswana).
Quality assurance was carried out for the quizzes from a
randomly selected 12% of the participant IDs following data
collection. The entry of their quizzes into the Access database was
checked for accuracy against the original paper quizzes and
inconsistencies were corrected.
Electronic data files were transported to the Johns Hopkins
Berman Institute of Bioethics for analysis. The Access database
was converted to a STATA file using Stat Transfer. Data were
analyzed using STATA 10.
Additional data, including demographic variables of study
participants, were obtained from the study team and linked with
quiz data. Subjects whose enrollment date did not match the date
of the enrollment quiz in the original dataset within a window of
30 days were eliminated from the dataset.
Variables
A quiz number (1–6) was assigned to the quizzes for each
participant ID, with the enrollment quiz always being quiz 1. An
indicator was created for participants who had 2 baseline quizzes,
as this signified that the participant was reported to have failed the
first enrollment quiz and was therefore given the enrollment quiz
twice. An indicator was created for each question so that we could
identify which questions were answered correctly, incorrectly, or
left blank, and an additional variable was created to sum the
number of questions answered correctly. Variables were created to
determine the time since the enrollment quiz and the time since
the previous quiz.
To ensure accurate interpretation of quiz items we asked 8
individuals who were unrelated to the trial and who were fluent in
both English and Setswana to independently review and back-
translate 4 of the Setswana quiz questions that were suspected to
have been incorrectly translated into Setswana after the quiz
analysis began.
Analysis
Bivariate and adjusted logistic regression analyses were
performed for the enrollment quizzes to determine associations
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as well as the likelihood of answering specific questions correctly at
enrollment. These logistic regression analyses were also performed
for the entire longitudinal dataset.
Bivariate analyses were performed to determine the odds of
passing each follow up quiz compared with the enrollment quiz
and compared with the previous quiz, as well as the odds of
passing a quiz by the interval since the last quiz.
Ethical Review
The Botswana IPT Trial was approved by the Botswana
Ministry of Health ethics committee and the CDC institutional
review board. This secondary analysis of comprehension quiz data
was approved by the Johns Hopkins Bloomberg School of Public
Health IRB and the Botswana ethics committee and CDC
institutional review board. The trial was registered at clinical-
trials.gov (NCT00164281).
Results
Data Included
From 2004 to 2006, 4,018 individuals agreed to screening for
the IPT trial. Of 1,860 individuals deemed ineligible for
participation, 25 were ineligible because they failed the compre-
hension quiz twice. A total of 1,995 participants were enrolled in
the IPT trial [43]. Of the 1,995 IPT trial participants, 1,971 had at
least one quiz available for data entry; a total of 5,882 baseline and
follow-up quizzes were entered into the database. The quizzes of
136 participants were excluded from analysis because their
enrollment dates did not match those in the study database, and
163 quizzes were excluded because they were not dated.
Additionally, during the 3-year period of observation, 176, 77,
46 and 11 participants voluntarily withdrew from the study, died,
attended study visits less than every 6 months on average or were
lost to follow-up, respectively. The final dataset contained 5,555
quizzes from 1,835 participant IDs. Of these, 33% had only an
enrollment quiz, while less than 2% of participants had more than
5 total quizzes (Table 1).
Quality assurance
A total of 495 randomly selected quizzes for 233 participants
were checked against the original paper quizzes. Six data entry
errors were detected, resulting in an error rate of less than 0.05%.
Descriptive data
The demographic characteristics of the study population are
displayed in Table 2. The study population was largely female
(72%), the median age was 33 years, and 32% were unemployed.
Sixty-five percent had received at least a secondary education,
28% had received no more than a primary education, 9% had
received education beyond the secondary level and 8% had no
formal education.
At enrollment, 47% of quizzes were taken in Setswana,
although longitudinally 66% of all quizzes were taken in Setswana.
Participants did not remain consistent in their choice of language
for quiz administration; of the participants who had more than 1
Table 1. Number of comprehension quizzes completed by
HIV-infected adults enrolled in a tuberculosis prevention trial,
Botswana 2004–2008.
Freq. %
Enrollment 1,835 33
2
nd attempt, enrollment 96 2
Quiz 2 1,436 26
Quiz 3 1,306 24
Quiz 4 853 15
Quiz 5 28 ,1
Quiz 6 1 ,1
Total 5,555 100
Comprehension quizzes were administered at screening for enrolment (Quiz 1)
and then every 6 months for a period of 36 months. However because not all
participants were administered all quizzes, ‘‘Quiz 2’’ – for instance – refers to the
second quiz taken regardless of the time elapsed since Quiz 1.
doi:10.1371/journal.pone.0022696.t001
Table 2. Characteristics of participants of the isoniazid
tuberculosis preventive therapy trial for whom
comprehension quizzes were available.
Characteristic N %
Sex
Female 1,318 72
Male 516 28
Missing 1 ,1
Age
,20 8 0.4
20–29 586 32
30–39 833 45
40–49 337 18
50–59 63 3
60–69 6 ,1
70+ 1 ,1
Missing 1 ,1
Occupation
Student 33 2
Administrator, Professional 156 8
Clerk, Technician 108 6
Service Worker, Sales 301 16
Crafts, Trades, Assemblers 107 6
Skilled Agricultural 5 0.3
Laborer, Miner, Construction, Transport 420 23
Unemployed 581 32
Other 122 7
Missing 2 ,1
Education
None 119 6
Primary 511 28
Secondary 1,033 56
Tertiary 164 9
Other 7 ,1
Missing 1 ,1
doi:10.1371/journal.pone.0022696.t002
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and 37% took all of their quizzes in Setswana. More than half
switched their quiz language preference throughout the trial.
Comprehension quiz scores
The final data set included enrollment quizzes from 1,835
participants. The overall median score at enrollment was 17
correct responses from among 20 true/false questions. At
enrollment, 1,475 participants (80%) passed on the first attempt,
and 342 (19%) failed initially but then passed on their second
attempt (the remainder did not have a score recorded). The
median score for those who failed on their first attempt was 15.
There was a decrease in the proportion of participants who
received a passing score for quiz 2 (63%). The odds of passing quiz
2 were significantly lower compared to quiz 1 (OR=0.4 [0.4,
0.5]). The proportion of participants passing the comprehension
quizzes rose following quiz 2; however the odds of passing
remained lower than those of passing quiz 1 for all except quiz 5,
for which the odds was not statistically significantly different than
quiz 1 (Table 3).
Passing over time
The proportion and odds of passing a repeat comprehension
quiz by time since the last quiz (months) are displayed in Table 3.
Of the participants with a score recorded, the proportion of
participants passing quizzes dropped from 69% when the quiz was
administered 1–6 months following the previous quiz to 65% at 7–
12 months and 61% at 13–18 months. The proportion rose at 19–
24 months and greater than 24 months. The odds of passing
compared to 1–6 months were not statistically significant at any of
these times.
Associations with Passing/Failing Comprehension
Quizzes
Higher rates of passing were significantly associated with higher
educational attainment. Table 4 shows the proportion of
participants passing the enrollment quiz by highest level of
education as well as the odds of passing compared with no formal
education. Those with secondary or tertiary education were
significantly more likely to pass than those with no formal
education. Participants over the median age of 33 had a lower
odds of passing the enrollment quiz compared with those age 33
and younger (OR=0.7 [0.5, 0.8]). Passing was not associated with
sex at enrollment (OR=1.1 [0.8, 1.4]).
Participants with higher education were more likely to take the
quizzes in English than those with lower education (Table 4).
Moreover, participants who took the quiz in English were more
likely to pass all quizzes than those who took the quiz in Setswana
(Table 5). The adjusted odds ratio indicated that individuals who
took the quiz in English were more likely to pass regardless of
highest level of education. Those with greater than primary
education were grouped together to conduct adjusted odds ratios.
Moreover, those with higher levels of education were more likely
to pass regardless of the language in which the quiz was taken
(Table 5).
Participants who failed quiz 1 on their initial attempt and then
passed on their second attempt (n=342), were more likely to fail
quiz 2 (93/251, OR 0.4, 95%CI0.3–0.5), quiz 3 (81/226, OR 0.4,
95%CI0.3–0.6), and quiz 4 (42/136, OR 0.5, 95%CI0.4–0.8) than
participants who passed quiz 1 on their first attempt.
Translation Reassessment
The translation reassessment conducted in the analysis phase
revealed discrepancies in how 4 of the 20 questions had been
translated. Notably, the eight new translators unanimously agreed
that question 9, ‘‘By taking the medicine I have a very small
chance of having damage to my liver,’’ was originally translated
into Setswana as ‘‘This medication will help protect my liver.’’
This error changed the correct answer from true to false for those
who took the quiz in Setswana. Subsequently, all data presented in
this manuscript were adjusted to take into account which quiz
response should be counted as correct. Additionally, 5 of the 8
translators back-translated the phrase ‘‘sugar pill’’ in questions 2
and 18 as ‘‘diabetes pill.’’ As there was some disagreement among
the translators, the data were not adjusted.
Response to specific quiz questions
Table 6 shows the rates of correct and incorrect answers at
enrollment for each question, as well as the odds of those
Table 3. Odds of passing comprehension quizzes 1–5 compared to quiz 1 & previous quiz; odds of passing comprehension
quizzes 1–5 by time since last quiz (months).
Quiz number
Quiz 1 Quiz 2 Quiz 3 Quiz 4 Quiz 5
n=1817 n=1418 n=1298 n=848 n=28
Proportion passing 80% 63% 72% 76% 86%
OR (95% CI) compared
to Quiz 1
0.4 (0.4, 0.5) 0.6 (0.5, 0.7) 0.7 (0.6, 0.9) 1.4 (0.5, 4.0)
OR (95% CI) compared
to previous quiz
0.4 (0.4, 0.5) 1.5 (1.2, 1.7) 1.2 (1.0, 1.5) 1.9 (0.6, 5.5)
Months since last quiz
1–6 7–12 13–18 19–24 .24
n=166 n=683 n=440 n=562 n=1742
Proportion passing 69% 65% 61% 69% 75%
OR (95% CI) compared
to 1–6 months
0.8 (0.6, 1.2) 0.7 (0.5, 1.1) 1.0 (0.7, 1.5) 1.3 (0.9, 1.9)
doi:10.1371/journal.pone.0022696.t003
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answering in Setswana. Over 90% of participants responded
correctly to questions that related to study purpose and
procedures. Twenty-three to 56% of participants answered
questions related to placebos/blinding, adherence, and risks
incorrectly. While participants who took the quiz in English were
more likely to answer many questions correctly than those who
took the quiz in Setswana, notably, those who took the quiz in
English were not more likely to answer the questions regarding
placebos correctly more frequently than those who took the quiz in
Setswana.
Across the entire dataset, questions related to study procedures
were most likely to be answered correctly, whereas questions
related to randomization, placebos, adherence, or risks were most
likely to be answered incorrectly (Table 7).
Likelihood of answering specific quiz questions correctly
at follow-up compared to enrollment
Table 8 shows the odds of answering each question correctly
compared with the enrollment quiz for quizzes 2–5. Participants
had greater odds of answering correctly questions related to
compensation (Q11), procedural questions related to providing a
urine sample and having a blood test (Q13, Q14), and the effect
that becoming ill with AIDS would have on participation (Q15).
Participants had lower odds of answering correctly questions
related to purpose (Q1, Q20), the procedural question related to
having an x-ray (Q5), questions related to risks of someone finding
out that the participant was HIV+ (Q8), having damage to the
liver (Q9), and the possibility of becoming nauseated (Q16). Least
likely to be correct was the question related to placebos (Q18).
Discussion
This study measured comprehension among 1,835 adults in
Botswana recruited for a longitudinal TB prevention trial through
repeated administration of a quiz to test participants’ comprehen-
sion of key study concepts. Participants who had a higher
education or took the quizzes in English rather than Setswana
demonstrated better comprehension. We also observed that
repetition of the quiz during the 2-year period improved
comprehension and that a significant proportion of participants
had difficulty responding correctly to questions about placebo,
randomization, and adverse events.
Having had more years of education was associated with higher
rates of passing, both at enrollment and during follow-up. These
data reinforce findings of many other studies that higher levels of
education are associated with higher levels of understanding of
medical research [10,44–47]. Although the mother tongue of over
90% of the participants was Setswana (data not shown), preferring
to take the quiz in English was associated with higher rates of
passing at enrollment and follow-up. Individuals who took the quiz
in English were more likely to pass regardless of highest level of
education, and those with higher levels of education were more
likely to pass regardless of the language in which the quiz was
taken. There was also an association between language and
educational attainment – those who chose to take the quiz in
English had higher levels of education, on average, than those who
chose to take the quiz in Setswana.
Table 4. Odds of passing quiz 1 by highest level of education; odds of taking quiz 1 in English by highest level of education.
Highest level of education
1
None Primary Secondary Tertiary
n=117 n=509 n=1021 n=162
Proportion passing at enrollment 73% 76% 83% 89%
OR (95% CI) compared to no education 1.2 (0.8, 1.9) 1.9 (1.2, 2.9) 3.0 (1.6, 5.7)
Proportion taking enrollment quiz in English
2 43% 43% 54% 78%
OR (95% CI) taking quiz in English compared to no formal
education
1.0 (0.7, 1.5) 1.6 (1.1, 2.4) 4.9 (2.9, 8.2)
OR (95% CI) taking quiz in English compared to previous level 1.0 (0.7, 1.5) 1.6 (1.3, 2.0) 3.0 (2.0, 4.5)
1Level of education coded as ‘‘Other’’ not included.
2Only records with score recorded included.
doi:10.1371/journal.pone.0022696.t004
Table 5. Unadjusted and adjusted odds of passing quizzes 1–
5 by language and education.
OR Passing (95% CI)
Unadjusted Adjusted
Quiz 1 (n=1809)
1
English 3.3 (2.5, 4.2) 3.1 (2.4, 4.0)
.primary education 1.7 (1.4, 2.2) 1.5 (1.2, 1.9)
Quiz 2 (n=1412)
English 1.5 (1.1, 1.9) 1.3 (1.0, 1.7)
.primary education 1.5 (1.2, 1.8) 1.4 (1.1, 1.7)
Quiz 3 (n=1293)
English 1.9 (1.4, 2.6) 1.4 (1.0, 2.0)
.primary education 2.4 (1.9, 3.1) 2.2 (1.7, 2.9)
Quiz 4 (n=846)
English 2.4 (1.6, 3.6) 1.4 (1.0, 2.0)
.primary education 2.8 (2.0, 3.8) 2.2 (1.7, 2.9)
Quiz 5 (n=22)
English ‘‘
.primary education 3 (0.3, 26.2) 2 (0.2, 17.9)
Odds ratios (OR) shown compare quiz results of those quizzes taken in English
to those quizzes taken in Setswana and compare participants who had greater
than primary education to those who had either only primary education or no
formal education.
1Only participants with a score, language, and level of education included;
participants with a level of education coded as ‘‘other’’ not included.
doi:10.1371/journal.pone.0022696.t005
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tended to answer questions correctly that related to study purpose
and procedures, while some questions related to randomization,
placebos, risks, and voluntariness were answered correctly less
than 70% of the time. While it is troubling that these particular
issues were problematic with respect to informed consent, it is
consistent with literature demonstrating that these items are
particularly likely to be misunderstood among subjects in both the
developed and developing world [1,3–5,20].
Various investigators have tested mechanisms to improve how
study information is delivered to participants with mixed results
[20,48–52]. Consent interventions that include more discussion
Table 6. Proportion of participants answering comprehension quiz 1 questions 1–20 correctly (English & Setswana); Odds of
answering correctly if quiz taken in English.
Comprehension Question Category English (n=969) Setswana (n=866) OR (95% CI)
Correct Incorrect Blank Correct Incorrect Blank
Q1 ‘‘This study is about preventing
tuberculosis in people living with
HIV/AIDS’’
Purpose 97% 1% 2% 90% 10% ,1% 18.0 (7.9, 41.5)
Q2 ‘‘I will know whether I am
taking a sugar pill’’
Placebo, Blinding 64% 34% 3% 65% 35% ,1% 1.03 (0.85, 1.3)
Q3 ‘‘This study will last for 3 years’’ Procedures 97% 1% 2% 96% 4% 0% 6.03 (2.5, 14.5)
Q4 ‘‘Ten teaspoons of blood will be
taken from my arm’’
Procedures 81% 16% 4% 66% 33% 1% 2.6 (2.08, 3.25)
Q5 ‘‘I will have a chest x-ray done’’ Procedures 97% ,1% 2% 100% ,1% 0% 0.55 (0.1, 2.98)
Q6 ‘‘I must continue taking the
medicine even if the medication
makes me ill’’
Procedures,
Voluntariness
77% 19% 3% 69% 30% 1% 1.72 (1.39,
2.14)
Q7 ‘‘I will no longer receive study
medication if I stop taking the
medication’’
Adherence 65% 30% 5% 44% 56% 1% 2.79 (2.3, 3.38)
Q8 ‘‘There is almost no chance that
someone will find out I am HIV
infected’’
Risks 85% 12% 3% 94% 6% 0% 0.43 (0.31,
0.61)
Q9 ‘‘By taking the medicine I have
a very small chance of having
damage
to my liver’’
Risks 81% 16% 3% 45% 54% 1% 6.0 (4.83, 7.46)
Q10 ‘‘I will be seen by a doctor or
nurse each time I return for a visit’’
Procedures 96% 2% 2% 98% 2% ,1% 0.86 (0.46, 1.6)
Q11 ‘‘I will not receive compensation
for transport costs to come to the
clinic’’
Compensation 89% 9% 2% 89% 11% ,1% 1.15 (0.85,
1.57)
Q12 ‘‘I can refuse to continue in the
study at any time’’
Voluntariness 77% 21% 2% 76% 24% 0% 1.12 (0.9, 1.39)
Q13 ‘‘I must give a urine sample at
each visit’’
Procedures 77% 20% 3% 86% 14% ,1% 0.61 (0.48,
0.79)
Q14 ‘‘My blood will be tested for
possible liver damage by the study
medication’’
Procedures, Risks 89% 9% 2% 93% 7% ,1% 0.71 (0.51, 1.0)
Q15 ‘‘If I become ill with AIDS I will
no longer be in the study’’
Procedures 74% 23% 3% 77% 22% ,1% 0.96 (0.77,
1.19)
Q16 ‘‘The isoniazid may make me
sick by making me feel nauseated’’
Risks 90% 8% 2% 87% 13% ,1% 1.61 (1.18,
2.18)
Q17 ‘‘Currently the Botswana
government recommends one year
of isoniazid preventive treatment for
people living with HIV/AIDS’’
Background 87% 11% 2% 84% 16% ,1% 1.55 (1.18,
2.03)
Q18 ‘‘A placebo is a sugar pill’’ Placebo 78% 19% 3% 82% 18% ,1% 0.89 (0.7, 1.13)
Q19 ‘‘If I think I am hurt by this
study I should contact the police
station in Gaborone’’
Risks 94% 4% 3% 94% 6% 0% 1.66 (1.08,
2.54)
Q20 ‘‘This study will help people
living with HIV/AIDS by finding out
if longer preventive treatment with
isoniazid will prevent TB’’
Purpose 96% 1% 2% 98% 2% 0% 1.65 (0.84,
3.27)
doi:10.1371/journal.pone.0022696.t006
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answering correctly if quiz taken in English.
Comprehension Question Category English (n=969) Setswana (n=866) OR (95% CI)
Correct Incorrect Blank Correct Incorrect Blank
Q1 ‘‘This study is about
preventing tuberculosis in
people living with HIV/AIDS’’
Purpose 97% 1% 2% 85% 15% ,1% 21.81(13.01, 36.54)
Q2 ‘‘I will know whether I am
taking a sugar pill’’
Placebo, Blinding 68& 29% 3% 64% 36% 1% 1.28 (1.14, 1.46)
Q3 ‘‘This study will last for 3
years’’
Procedures 97% 1% 2% 96% 4% ,1% 3.73 (2.3, 6.05)
Q4 ‘‘Ten teaspoons of blood
will be taken from my arm’’
Procedures 80% 17% 4% 71% 28% 1% 1.89 (1.64, 2.18)
Q5 ‘‘I will have a chest x-ray
done’’
Procedures 94% 3% 3% 97% 3% ,1% 0.91 (0.66, 1.26)
Q6 ‘‘I must continue taking
the medicine even if the
medication makes me ill’’
Procedures,
Voluntariness
80% 17% 3% 75% 24% 1% 1.53 (1.33, 1.76)
Q7 ‘‘I will no longer receive
study medication if I stop
taking the medication’’
Adherence 57% 40% 4% 54% 46% 1% 1.21 (1.08, 1.36)
Q8 ‘‘There is almost no chance
that someone will find out I
am HIV infected’’
Risks 82% 15% 3% 90% 9% ,1% 0.56 (0.48, 0.67)
Q9 ‘‘By taking the medicine I
have a very small chance of
having damage to my liver’’
Risks 73% 25% 3% 46% 53% 1% 3.45 (3.05, 3.91)
Q10 ‘‘I will be seen by a
doctor or nurse each time
I return for a visit’’
Procedures 95% 3% 2% 97% 3% ,1% 0.95 (0.69, 1.33)
Q11 ‘‘I will not receive
compensation for transport
costs to come to the clinic’’
Compensation 90% 8% 2% 91% 8% 1% 0.99 (0.8, 1.21)
Q12 ‘‘I can refuse to continue
in the study at any time’’
Voluntariness 75% 23% 2% 74% 25% ,1% 1.14 (0.99, 1.29)
Q13 ‘‘I must give a urine
sample at each visit’’
Procedures 85% 12% 3% 92% 8% ,1% 0.58 (0.49, 0.7)
Q14 ‘‘My blood will be
tested for possible liver
damage by the study
medication’’
Procedures, Risks 91% 7% 2% 95% 4% ,1% 0.58 (0.46, 0.74)
Q15 ‘‘If I become ill with
AIDS I will no longer be in
the study’’
Procedures 80% 17% 3% 87% 12% ,1% 0.69 (0.59, 0.8)
Q16 ‘‘The isoniazid may make
me sick by making me feel
nauseated’’
Risks 77% 21% 3% 79% 21% ,1% 0.99 (0.87, 1.14)
Q17 ‘‘Currently the Botswana
government recommends one
year of isoniazid preventive
treatment for people living
with HIV/AIDS’’
Background 84% 14% 2% 82% 18% ,1% 1.34 (1.15, 1.57)
Q18 ‘‘A placebo is a sugar pill’’ Placebo 75% 22% 3% 66% 32% 1% 1.65 (1.45, 1.88)
Q19 ‘‘If I think I am hurt by
this study I should contact the
police station in Gaborone’’
Risks 94% 3% 3% 93% 7% ,1% 2.25 (1.68, 3.0)
Q20 ‘‘This study will help
people living with HIV/AIDS by
finding out if longer preventive
treatment with isoniazid will
prevent TB’’
Purpose 96% 2% 2% 93% 7% ,1% 4.46 (3.06, 6.51)
doi:10.1371/journal.pone.0022696.t007
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information [45,53–55]. With regard to randomization in
particular, there is evidence to suggest that providing explanations
as to why subjects are being randomized (and not just how)
improves subjects’ understanding [8].
Quiz 2 was administered at 6 months after enrolment to a
minority of participants: the range in the time since the
enrolment quiz when quiz 2 was administered was broad. This
heterogeneous timing of quiz 2’s administration combined scores
of participants who had taken the quiz 6 months previously with
some who had received it years before and may have forgotten
certain elements. In addition to this limitation, the observation
that repeated quizzes improved comprehension may represent
survivor bias: those who understood the study requirements may
have been more likely to remain enrolled than those who did not.
A further word of caution is that since there were only 20
comprehension questions, missing just two questions resulted in a
10% lower score, and although such a drop may have been
determined to be a statistically significant decline, it may have not
been meaningful with respect to actual comprehension. Future
work might determine which subsets of quiz questions were
considered by investigators to be particularly critical to
participant understanding and examine trends in correctly
answering these questions over time.
Back-translation of several items from the Setswana version of
the quiz revealed discrepancies between the Setswana and English
versions. While we adjusted what counted as a correct answer to
correspond to the accurate meaning of one particular question,
this likely introduced some confusion, particularly for the 53%
who took the quiz in different languages on different study visits.
Confusion may have been most acute for the items related to
placebo. Specifically, 5 of 8 of our post-study translators reported
that the phrase ‘‘sugar pill’’ from the Setswana quiz could be
understood colloquially as ‘‘diabetes pill’’ because, according to
the translators, in vernacular Setswana the term for ‘‘sugar’’ and
‘‘diabetes’’ is medically the same [56]. Translators further
suggested that the meaning of the phrase is influenced by context;
as the study was not about diabetes but TB prevention it should
Table 8. Odds of answering comprehension quiz questions 1–20 correctly at Quizzes 2–5 compared to enrollment quiz.
Comprehension Question
Quiz 2 OR (95% CI)
(n=1417)
Quiz 3 OR (95% CI)
(n=1298)
Quiz 4 OR (95% CI)
(n=848)
Quiz 5 OR (95% CI)
(n=28)
Q1 ‘‘This study is about preventing tuberculosis in
people living with HIV/AIDS’’
0.4 (0.3, 0.6) 0.3 (0.3, 0.5) 0.3 (0.3, 0.4) 0.3 (0.1, 1.0)
Q2 ‘‘I will know whether I am taking a sugar pill’’ 1.0 (0.9, 1.2) 1.1 (0.9, 1.2) 1.1 (0.9, 1.3) 2.0 (0.8, 4.9)
Q3 ‘‘This study will last for 3 years’’ 0.6 (0.4, 0.9) 0.7 (0.4, 1.0) 0.8 (0.5, 1.4) ‘
Q4 ‘‘Ten teaspoons of blood will be taken from my arm’’ 0.9 (0.7, 1.0) 1.0 (0.8, 1.2) 1.1 (0.9, 1.4) 2.7 (0.8, 9.0)
Q5 ‘‘I will have a chest x-ray done’’ 0.1 (0.04, 0.2) 0.1 (0.02, 0.1) 0.1 (0.02, 0.2) 0.1 (0.01, 0.8)
Q6 ‘‘I must continue taking the medicine even if the
medication makes me ill’’
0.9 (0.8, 1.0) 1.5 (1.2, 1.7) 1.8 (1.5, 2.3) 2.0 (0.7, 5.7)
Q7 ‘‘I will no longer receive study medication if I stop
taking the medication’’
0.7 (0.6, 0.8) 1.0 (0.9, 1.2) 1.4 (1.2, 1.6) 0.9 (0.4, 1.9)
Q8 ‘‘There is almost no chance that someone will find
out I am HIV infected’’
0.7 (0.6, 0.9) 0.7 (0.6, 0.9) 0.8 (0.6, 1.1) 0.9 (0.3, 3.0)
Q9 ‘‘By taking the medicine I have a very small chance
of having damage to my liver’’
0.5 (0.4, 0.6) 0.6 (0.5, 0.7) 0.6 (0.5, 0.8) 0.7 (0.3, 1.5)
Q10 ‘‘I will be seen by a doctor or nurse each time I
return for a visit’’
0.6 (0.4, 0.9) 0.7 (0.4, 1.0) 0.9 (0.5, 1.5) ‘
Q11 ‘‘I will not receive compensation for transport
costs to come to the clinic’’
1.3 (1.0, 1.7) 1.4 (1.1, 1.9) 1.8 (1.3, 2.5) ‘
Q12 ‘‘I can refuse to continue in the study at any time’’ 0.6 (0.5, 0.7) 0.9 (0.8, 1.1) 1.2 (0.9, 1.4) 0.9 (0.4, 2.1)
Q13 ‘‘I must give a urine sample at each visit’’ 3.4 (2.6, 4.4) 4.3 (3.2, 5.7) 3.8 (2.7, 5.2) 2.8 (0.7, 11.7)
Q14 ‘‘My blood will be tested for possible liver damage
by the study medication’’
1.7 (1.3, 2.3) 2.7 (1.9, 3.8) 3.6 (2.2, 5.7) ‘
Q15 ‘‘If I become ill with AIDS I will no longer be
in the study’’
2.5 (2.1, 3.1) 2.7 (2.2, 3.3) 3.6 (2.7, 4.8) 8.0 (1.1, 59.0)
Q16 ‘‘The isoniazid may make me sick by making me
feel nauseated’’
0.3 (0.2, 0.3) 0.4 (0.3, 0.4) 0.4 (0.3, 0.5) 0.4 (0.2, 1.1)
Q17 ‘‘Currently the Botswana government recommends
one year of isoniazid preventive treatment for people living
with HIV/AIDS’’
0.7 (0.6, 0.8) 0.7 (0.6, 0.9) 0.8 (0.6, 1.0) 0.9 (0.3, 2.7)
Q18 ‘‘A placebo is a sugar pill’’ 0.4 (0.3, 0.5) 0.5 (0.4, 0.5) 0.5 (0.4, 0.6) 0.5 (0.2, 1.1)
Q19 ‘‘If I think I am hurt by this study I should contact the
police station in Gaborone’’
0.8 (0.6, 1.0) 1.0 (0.7, 1.3) 0.9 (0.6, 1.2) ‘
Q20 ‘‘This study will help people living with HIV/AIDS by
finding out if longer preventive treatment with isoniazid
will prevent TB’’
0.3 (0.2, 0.5) 0.3 (0.2, 0.4) 0.2 (0.1, 0.3) 0.3 (0.1, 1.1)
doi:10.1371/journal.pone.0022696.t008
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took the quiz in English responded incorrectly to quiz items related
to placebos suggests that placebo remains a difficult concept to
understand, regardless of language [5,57,58].
This discrepancy highlights the challenge of creating consent
documents and other study materials in multiple languages.
Presenting study information clearly is difficult in one’s native
language; accurately translating what are sometimes abstract or
unusual concepts (such as randomization) has been consistently
documented as problematic in international research [59–64].
True/false quizzes are an imperfect means of measuring
understanding, as they allow participants to guess answers as well
as to repeat back what they heard, whether or not they understood
it. Research has demonstrated that asking participants to voice, in
their own words, their understanding of research more thoroughly
reveals what subjects understand [48,65]. At the same time, the
current standard is for no comprehension assessment to be
conducted whatsoever, despite understanding being one of the
four core elements of valid informed consent [66]. As such,
conducting any type of assessment, including a quiz, is a significant
step toward honoring this core tenet of consent.
Conclusion
This study demonstrated that participants in a large 3-year
clinical trial in Africa generally understood key study information.
Importantly, it also demonstrated that administration of a quiz
both at enrollment and follow-up was feasible and served as a
useful means of determining whether subjects had sufficient
information to enroll in the trial. Participants’ understanding of
information decreased slightly following enrollment, but the rate of
passing improved following the first re-assessment, suggesting that
providing quizzes over the course of an ongoing clinical trial may
reinforce key study information. Assessments of understanding
should be incorporated into future research, particularly in
relation to topics that may be less familiar to research participants.
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